Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1962 1
1972 1
1980 1
1982 1
1987 1
1993 2
1996 3
1999 1
2000 1
2001 5
2002 3
2003 7
2004 9
2005 18
2006 14
2007 17
2008 30
2009 19
2010 29
2011 21
2012 18
2013 31
2014 12
2015 15
2016 6
2017 4
2018 5
2019 3
2020 8
2021 4
Text availability
Article attribute
Article type
Publication date

Similar articles for PMID: 17699221

262 results
Results by year
Filters applied: . Clear all
Page 1
Implementation of 'K/DOQI Clinical Practice Guidelines for Bone Metabolism and Disease in Chronic Kidney Disease' after the introduction of cinacalcet in a population of patients on chronic haemodialysis.
Arenas MD, Alvarez-Ude F, Gil MT, Moledous A, Malek T, Nuñez C, Devesa R, Carretón MA, Soriano A. Arenas MD, et al. Nephrol Dial Transplant. 2007 Jun;22(6):1639-44. doi: 10.1093/ndt/gfl840. Epub 2007 Feb 3. Nephrol Dial Transplant. 2007. PMID: 17277339
Impact of vitamin D dose on biochemical parameters in patients with secondary hyperparathyroidism receiving cinacalcet.
Wilkie M, Pontoriero G, Macário F, Yaqoob M, Bouman K, Braun J, von Albertini B, Brink H, Maduell F, Graf H, Frazão JM, Bos WJ, Torregrosa V, Saha H, Reichel H, Zani VJ, Carter D, Messa P. Wilkie M, et al. Nephron Clin Pract. 2009;112(1):c41-50. doi: 10.1159/000212102. Epub 2009 Apr 10. Nephron Clin Pract. 2009. PMID: 19365139 Clinical Trial.
The OPTIMA study: assessing a new cinacalcet (Sensipar/Mimpara) treatment algorithm for secondary hyperparathyroidism.
Messa P, Macário F, Yaqoob M, Bouman K, Braun J, von Albertini B, Brink H, Maduell F, Graf H, Frazão JM, Bos WJ, Torregrosa V, Saha H, Reichel H, Wilkie M, Zani VJ, Molemans B, Carter D, Locatelli F. Messa P, et al. Clin J Am Soc Nephrol. 2008 Jan;3(1):36-45. doi: 10.2215/CJN.03591006. Clin J Am Soc Nephrol. 2008. PMID: 18178780 Free PMC article. Clinical Trial.
Cinacalcet HCl, an oral calcimimetic agent for the treatment of secondary hyperparathyroidism in hemodialysis and peritoneal dialysis: a randomized, double-blind, multicenter study.
Lindberg JS, Culleton B, Wong G, Borah MF, Clark RV, Shapiro WB, Roger SD, Husserl FE, Klassen PS, Guo MD, Albizem MB, Coburn JW. Lindberg JS, et al. J Am Soc Nephrol. 2005 Mar;16(3):800-7. doi: 10.1681/ASN.2004060512. Epub 2005 Feb 2. J Am Soc Nephrol. 2005. PMID: 15689407 Free article. Clinical Trial.
Cinacalcet HCl and concurrent low-dose vitamin D improves treatment of secondary hyperparathyroidism in dialysis patients compared with vitamin D alone: the ACHIEVE study results.
Fishbane S, Shapiro WB, Corry DB, Vicks SL, Roppolo M, Rappaport K, Ling X, Goodman WG, Turner S, Charytan C. Fishbane S, et al. Clin J Am Soc Nephrol. 2008 Nov;3(6):1718-25. doi: 10.2215/CJN.01040308. Clin J Am Soc Nephrol. 2008. PMID: 18945995 Free PMC article. Clinical Trial.
262 results